Biopsy Devices Market Size, Share & Trends Analysis Report By Product (Needle-based Biopsy Guns, Biopsy Guidance Systems, Biopsy Forceps, Biopsy Needles), By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global biopsy devices market size was valued at USD 2.11 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 7.1% from 2023 to 2030. The growing prevalence of cancer worldwide, the presence of untapped opportunities in emerging economies, especially in Asia Pacific, and improving healthcare infrastructure in these regions are among the key trends encouraging industry growth.

The COVID-19 pandemic moderately impacted the market in 2020. With healthcare professionals majorly focusing on COVID-19 patients, prioritizing cancer patients was a challenge. With an increased focus to avoid being infected with the virus, a large number of individuals preferred minimum visits to healthcare settings. This negatively impacted the biopsy market to a certain extent.

However, with the world completely returning to normalcy and increasing incidences of cancer, the market recovered quickly. Moreover, with rapid advancements in oncology, new product launches, and a strong pipeline of biopsy devices, the market further represents a lucrative growth opportunity over the forecast period.

The increasing incidence of cancer worldwide is the major factor driving the demand for biopsy devices. For instance, in 2022, an estimated 1.9 million new cancer cases will be diagnosed in the U.S., according to the American Cancer Society. The rising incidence of cancer is encouraging the development of more effective, safe, and advanced biopsy procedures.

Minimally invasive medical procedures offer several advantages, thus bolstering their popularity. Such procedures result in the quicker recovery of patients and are less traumatic. Research results published by manufacturers suggest that minimally invasive surgeries are rapidly replacing invasive surgeries and providing higher patient satisfaction levels.

Spiraling demand for less invasive surgeries and disposable biopsy devices is anticipated to propel the industry's growth. Technologically advanced biopsy guidance systems, such as vacuum-assisted guns, are gaining popularity among patients and healthcare providers. The widening base of the geriatric population and the introduction of cost-effective and advanced devices are anticipated to further boost the growth of the market.

Growing cancer-related spending is triggering the need for effective diagnostic procedures. Government and healthcare regulatory bodies all across the world are constantly engaged in curbing the high costs associated with the treatment of cancer. Primary and secondary healthcare centers in emerging nations are encouraging patients to undergo regular diagnostic examinations. The use of biopsy devices involves a relatively lesser number of hospital visits and therefore, is economically viable.

Product Insights

Needle-based biopsy guns held the leading share of over 40.0% in 2022. Surging demand for these guns to acquire samples from soft tissues of internal organs such as kidneys, breasts, and lungs is projected to contribute to the growth of the overall market during the forecast period. The rising need for rapid and gentle procurement of cell samples for biopsy is one of the key factors supplementing the growth of the segment.

Moreover, the growing demand for vacuum-assisted devices is influencing market growth positively. These devices are manual, semi-automatic, and automatic with a spring-loaded mechanism for minimally invasive insertion to obtain samples for laboratory testing. Such devices demonstrate high efficiency and precision in the withdrawal of large volumes and excellent quality tissue samples with a minimal number of passes through the skin. Therefore, market players are increasingly focusing on investing in R&D in order to have a strong product pipeline and meet the increasing demand for vacuum-assisted devices.

For instance, in August 2022, TransMed7, LLC declared a “First in Human” clinical case of the commercial production version of a Heron XPS device. It is a member of the new Heron family of vacuum-assisted, single insertion/multiple collection soft tissue biopsy devices.

The biopsy needles segment is anticipated to witness significant growth over the forecast period. Regulatory approvals of new products enable greater precision in the diagnosis and treatment of lung cancer. For instance, in September 2022, Serpex Medical received U.S. FDA approval for its Compass Steerable Needles. The company seeks to use these needles to enable greater precision and access to improve the diagnosis and treatment of lung cancer.

Regional Insights

North America held a leading revenue share of over 40.0% in 2022. Due to established market players domiciled in the region, it will continue to account for a substantial share of the market throughout the forecast period. High market penetration rates of technologically advanced devices such as vacuum-assisted biopsy systems and rapidly growing demand for disposable devices are expected to augur well for the regional market.

The number of biopsies done in the U.S. is the highest. For instance, according to a research study, “The Breast”, published in 2018, there are 3 million breast biopsies performed in the U.S. annually. Moreover, the U.S. FDA has a less stringent regulatory approval process for medical devices since they are considered at moderate risk. There are several government health initiatives aimed at encouraging individuals to undertake regular cancer screening.

Asia Pacific represents great opportunities for the growth of the market. Rapidly improving healthcare infrastructure in emerging Asia Pacific countries, the presence of high unmet patient needs, and the increasing incidence of cancer are anticipated to stimulate the growth of the regional market.

According to Global Cancer Statistics 2020, one-half of all cases and 58.3% of cancer deaths were estimated to occur in Asia. Furthermore, reforms introduced in India and China are poised to increase the purchasing power of healthcare establishments, thereby escalating industry growth.

Key Companies & Market Share Insights

Key players in the market are majorly investing in R&D in order to develop products that are technologically advanced, which will help them retain a strong position in the market as well. For instance, in August 2022, Devicor Medical Products, Inc. announced the launch of the Mammotome DualCore Dual Stage Core Biopsy System. Some prominent players in the global biopsy devices market include:

• Cardinal Health Inc.

• Hologic, Inc.

• Danaher Corporation

• CONMED Corporation

• Cook Medical

• DTR Medical

• INRAD, Inc.

• Devicor Medical Products Inc.

• Gallini Srl

• TransMed7, LLC

Biopsy Devices Market Report Scope

Global Biopsy Devices Market Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global biopsy devices market report on the basis of product and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Needle-based Biopsy Guns

    • Vacuum-assisted Biopsy (VAB) Devices

    • Fine Needle Aspiration Biopsy (FNAB) Devices

    • Core Needle Biopsy (CNB) devices

  • Biopsy Guidance Systems

    • Manual

    • Robotic

  • Biopsy Needles

    • Disposable

    • Reusable

  • Biopsy Forceps

    • General Biopsy Forceps

    • Hot Biopsy Forceps

  • Others

    • Brushes

    • Curettes

    • Punches 

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

  • U.S.

  • Canada

  • Europe

  • Germany

  • U.K.

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

  • Asia Pacific

  • Japan

  • India

  • China

  • South Korea

  • Thailand

  • Australia

  • Latin America

  • Brazil

  • Mexico

  • Argentina

  • Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait